MHLW Warns Of Link Between Thrombosis And Orally Administered Estrogen Therapies
This article was originally published in PharmAsia News
Executive Summary
Japan’s MHLW issued a warning regarding the possible link between thrombosis and the use of orally administered estrogen formulations such as low-dose formulations and dysmenorrhea drugs regardless of age, smoking habits, obesity, or family history, instructing the FPMAJ to place warnings on drug package inserts.